DUBLIN, Oct. 5, 2017 /PRNewswire/ -- Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017 American Society for Dermatologic Surgery (ASDS) meeting in Chicago, Illinois from October 5-8.
The meeting will be held at the Exhibit Hall, Riverside Center and the scheduled times (noted in local Central Time) of the Allergan presentations, titles and authors are as follows:
Real-World Use of ATX-101 Treatment for Reduction of Submental Fat: Final Data from CONTOUR
Improvements in Submental Contour Achieved With ATX-101 Treatment Are Maintained Over Time: 3-Year Follow-up of Subjects from the Phase 3 REFINE Trials
OnabotulinumtoxinA for Treatment of Moderate to Severe Horizontal Frontalis Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study
Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study
Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines
OnabotulinumtoxinA (Botox®) Displays Superior Activity to IncobotulinumtoxinA Drug Product (Xeomin®) in Multiple in Vitro and in Vivo Assays
The Psychological Impacts of Forehead, Glabellar, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies
Juvéderm Vollure XC Is Safe and Effective for Long-term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study
VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study
VYC-17.5L is Safe and Effective for Long-Term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study
Lip and Perioral Enhancement With HA Dermal Fillers in Individuals With Skin of Color
Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations from the HARMONY Study
Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian and Hispanic
Skin Laxity Is Unchanged Among ATX-101 Treatment Responders: Post hoc Analysis of Phase 3 Data
Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results from a Post hoc Analysis
Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines
A Customized Approach for Arm Fat Reduction using Cryolipolysis
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model ? Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.
SOURCE Allergan plc
These press releases may also interest you